• OraSure won FDA emergency use authorization for its second-generation OraQuick Ebola 2.0 rapid antigen test.
• Test covers suspected live patients using whole blood, also cadaveric oral fluid; results in 30 minutes without instruments.
• BARDA supported development under a 2022 contract; OraSure is ramping up production amid the Central Africa outbreak.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OraSure Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607211630PRIMZONEFULLFEED9765828) on July 21, 2026, and is solely responsible for the information contained therein.